GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Goodwill-to-Asset

Celyad Oncology (XBRU:CYAD) Goodwill-to-Asset : 0.00 (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Celyad Oncology's Goodwill for the quarter that ended in Jun. 2023 was €0.00 Mil. Celyad Oncology's Total Assets for the quarter that ended in Jun. 2023 was €12.18 Mil.


Celyad Oncology Goodwill-to-Asset Historical Data

The historical data trend for Celyad Oncology's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Goodwill-to-Asset Chart

Celyad Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 -

Celyad Oncology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - 0.01 - -

Competitive Comparison of Celyad Oncology's Goodwill-to-Asset

For the Biotechnology subindustry, Celyad Oncology's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celyad Oncology's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Goodwill-to-Asset falls into.



Celyad Oncology Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Celyad Oncology's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Goodwill to Asset (A: Dec. 2022 )=Goodwill/Total Assets
=0/19.716
=

Celyad Oncology's Goodwill to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Goodwill to Asset (Q: Jun. 2023 )=Goodwill/Total Assets
=0/12.178
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celyad Oncology  (XBRU:CYAD) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Celyad Oncology Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Celyad Oncology (XBRU:CYAD) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines